Cervical Cancer Screening

• Autores: George F. Sawaya, Megan J. Huchko
• Localización: Medical clinics of North America, ISSN 0025-7125, Vol. 101, Nº. 4, 2017 (Ejemplar dedicado a: Disease Prevention), págs. 743-753
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cervical cancer screening in the United States has accompanied profound decreases in cancer incidence and mortality over the last half century. Two screening strategies are currently endorsed by US-based guideline groups: (1) triennial cytology for women aged 21 to 65 years, and (2) triennial cytology for women aged 21 to 29 years followed by cytology plus testing for high-risk human papillomavirus types every 5 years for women aged 30 years and older. Providing women with affordable, easily accessible screening, follow-up of abnormal tests, and timely treatment will result in the greatest impact of screening on cervical cancer incidence and mortality.